Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502622 | 0.70 | DRD2 (0.36) | MAOAMAOB | |
| SCHEMBL18706436 | 0.70 | — | — | |
| SCHEMBL20477699 | 0.67 | TSHR (0.42) | TSHRCYP1A2MAOAMAOB | |
| SCHEMBL157430 | 0.67 | — | — | |
| SCHEMBL1623564 | 0.67 | — | — | |
| SCHEMBL1162905 | 0.67 | TSHR (0.42) | TSHRCYP1A2MAOAMAOB | |
| SCHEMBL7205467 | 0.66 | DRD2 (0.42) | MAOB | |
| SCHEMBL23766 | 0.64 | — | — | |
| SCHEMBL1162903 | 0.64 | TSHR (0.44) | TSHRCYP1A2MAOAMAOB | |
| SCHEMBL29507678 | 0.64 | TSHR (0.44) | TSHRCYP1A2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961374-A1 | FRAGRANCE COMPOSITIONS | The Procter & Gamble Company (US) | 2016-01-06 | — | — | EP | claimed |
| WO-2015089246-A1 | FRAGRANCE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2015-06-18 | — | — | WO | claimed |
| EP-2563508-A2 | DELIVERY PARTICLE | The Procter & Gamble Company (US) | 2013-03-06 | — | — | EP | claimed |
| WO-2012040444-A2 | TREATMENT OF PATIENTS WITH INCIPIENT ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | claimed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | claimed |
| WO-2010079468-A2 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-15 | — | — | WO | claimed |
| US-20090227492-A1 | TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS | WOODRUFF TRENT MARTIN | 2009-09-10 | — | — | US | claimed |
| EP-1465861-B1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | claimed |
| US-20090004264-A1 | METHODS FOR TREATING AND AMELIORATING THE SYMPTONS OF INFLAMMATORY BOWEL DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-01-01 | — | — | US | claimed |
| US-20080113904-A1 | Treatment of Neurological Conditions Using Complement C5a Receptor Modulators | PROMICS PTY LIMITED (AU) | 2008-05-15 | — | — | US | claimed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | claimed |
| CN-1997664-A | Compounds that block the C5A receptor and their use in therapy | ALLIGATOR BIOSCIENCE AB PUBL (SE) | 2007-07-11 | — | — | CN | claimed |
| CN-1261449-C | Melanocyte-stimulating hormone inhibitors | AJINOMOTO KK (JP) | 2006-06-28 | — | — | CN | claimed |
| EP-1465861-A4 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1465861-A1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | claimed |
| WO-2003053912-A1 | α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | claimed |
| EP-0931074-B1 | CONDENSED 4,5,6,7-TETRAHYDROBENZO C]THIOPHENES AS ENHANCER FOR CELL DIFFERENTIATION INDUCTION FACTOR ACTION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-09-26 | — | — | US | claimed |
| CN-1341119-A | Melanocyte-stimulating hormone inhibitors | AJINOMOTO KK (JP) | 2002-03-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004264-A1 | METHODS FOR TREATING AND AMELIORATING THE SYMPTONS OF INFLAMMATORY BOWEL DISEASES | C5AR2, C5AR1, C3AR1 | TSHR 1425/4885CYP1A2 4108/4885MAOA 2823/4885 |
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, BACE1, IAPP | TSHR 3457/4885CYP1A2 2292/4885MAOA 79/4885 |
| US-20090227492-A1 | TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS | C3AR1, C5AR1, C5AR2 | TSHR 479/4885CYP1A2 3863/4885MAOA 1372/4885 |
| US-20080113904-A1 | Treatment of Neurological Conditions Using Complement C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | TSHR 479/4885CYP1A2 3863/4885MAOA 1372/4885 |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | APBA1, APP, BACE1 | TSHR 3640/4885CYP1A2 3492/4885MAOA 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.